Cited by 644Multiple Sclerosis Research StudiesNeuroinflammation and Neurodegeneration MechanismsSingle-cell and spatial transcriptomics

Neuronal vulnerability and multilineage diversity in multiple sclerosis

Open access
Schirmer, Lucas, Velmeshev, Dmitry, Holmqvist, Staffan, Kaufmann, Max, Werneburg, Sebastian, Jung, Diane, Vistnes, Stephanie, Stockley, John H. +16 more·2019·Nature

Abstract

Multiple sclerosis (MS) is a neuroinflammatory disease with a relapsing-remitting disease course at early stages, distinct lesion characteristics in cortical grey versus subcortical white matter and neurodegeneration at chronic stages. Here we used single-nucleus RNA sequencing to assess changes in expression in multiple cell lineages in MS lesions and validated the results using multiplex in situ hybridization. We found selective vulnerability and loss of excitatory CUX2-expressing projection neurons in upper-cortical layers underlying meningeal inflammation; such MS neuron populations exhibited upregulation of stress pathway genes and long non-coding RNAs. Signatures of stressed oligodendrocytes, reactive astrocytes and activated microglia mapped most strongly to the rim of MS plaques. Notably, single-nucleus RNA sequencing identified phagocytosing microglia and/or macrophages by their ingestion and perinuclear import of myelin transcripts, confirmed by functional mouse and human culture assays. Our findings indicate lineage- and region-specific transcriptomic changes associated with selective cortical neuron damage and glial activation contributing to progression of MS lesions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-019-1404-z

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Focal lesions such as those in the brainstem result in axonal loss, and cortical demyelination is associated with selective neuronal loss; both are prominent determinants of progression.

    “It is well established that focal lesions such as those in the brainstem result in axonal loss, and that cortical demyelination, which occurs independently of white matter lesions, is associated with selective neuronal loss18; both these degenerative features are prominent determinants of progression18,19.”

    From Locus for severity implicates CNS resilience in progression of multiple sclerosis (2023) · cites this paper as [18]

    The Abstract links focal plaques with progressive white-matter axonal damage, and the Results report selective loss of CUX2-expressing neurons in demyelinated cortical lesions (page numbers unavailable). The copy does not establish the brainstem-specific example, that cortical demyelination occurs independently of white-matter lesions, or that both degenerative features are prominent determinants of progression. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Homozygous rs10191329 risk allele carriers demonstrated more severe MS-specific brainstem and cortical pathology, which result in axonal and neuronal degeneration respectively and drive progression.

    “Besides these clinical differences, homozygous rs10191329 risk allele carriers also demonstrated more severe MS-specific brainstem and cortical pathology, which result in axonal and neuronal degeneration respectively and drive progression18,19.”

    From Locus for severity implicates CNS resilience in progression of multiple sclerosis (2023) · cites this paper as [18]

    The Results report degeneration and selective loss of upper-layer excitatory neurons in cortical MS lesions, and the Discussion links cortical neurodegeneration to regions involved in progression. The paper does not establish that homozygous rs10191329 carriers have more severe pathology, nor does it report brainstem pathology or show that these changes drive progression. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • In the Schirmer et al. dataset, microglial cluster 1 was selectively enriched within acute/chronic active MS lesions.

    “This cluster was selectively enriched within acute/chronic active MS lesions (Fig. 4 C and D and Dataset S7).”

    From Acute TREM2 inhibition depletes MAFB-high microglia and hinders remyelination (2025) · cites this paper as [37]

    The Results (page unavailable) map activated microglia to the boundaries of chronic-active MS lesions, and Extended Data Fig. 5 describes microglial subtypes associated with inflammatory lesion stages. Our copy does not identify the mapped cells as “microglial cluster 1” or establish selective enrichment in both acute and chronic-active lesions. (LLM, conf=0.83)

    Experimental — accuracy not yet measured
  • Microglia contribute to both the development and progression of MS.

    “Together, these results suggest microglia contribute to both the development and progression of MS”

    From Activated microglia drive demyelination via <scp>CSF1R</scp> signaling (2021) · cites this paper as Schirmer et al., 2019

    The Results (page not available in our copy) identify activated, phagocytosing microglia at the rims of chronic-active MS lesions, and the Discussion links microglial activation there to lesion areas involved in progression. These findings support a suggested role in progression, but the paper does not establish a role for microglia in the initial development of MS. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Reanalysis of the human MS snRNA-seq dataset from Schirmer et al. showed that microglia coexpressed TREM2 and MAFB.

    “A reanalysis of the human MS snRNA-seq dataset from Schirmer et al. (37) showed that microglia coexpressed TREM2 and MAFB (SI Appendix, Fig. S9 A–D).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [50]Jahn O Tenzer S Bartsch N Patzig J Werner HB Humana Press Totowa, NJ 2013 79 335 353

Cited by

Sorted by citations

Authors
Schirmer, L., Velmeshev, D., Holmqvist, S., Kaufmann, M., Werneburg, S., Jung, D., Vistnes, S., Stockley, J. H., Young, A., Steindel, M., Tung, B., Goyal, N., Bhaduri, A., Mayer, S., Engler, J. B., Bayraktar, O. A., Franklin, R. J. M., Haeussler, M., Reynolds, R., Schafer, D. P., Friese, M. A., Shiow, L. R., Kriegstein, A. R., & Rowitch, D. H.
Affiliations
  • University of California, San Francisco (US)
  • Wellcome/MRC Cambridge Stem Cell Institute (GB)
  • Universität Hamburg (DE)
  • University of Massachusetts Chan Medical School (US)
  • University of California, Santa Cruz (US)
  • Imperial College London (GB)
Corresponding author
  • Kriegstein, Arnold R.
  • Rowitch, David H.
Venue
Nature
Published
2019-07-17
Volume
573
Issue
7772
Pages
75-82
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2951560273
Cited by
638
References
56
Citations by year
2026: 69 · 2025: 100 · 2024: 118 · 2023: 91 · 2022: 99 · 2021: 89 · 2020: 56 · 2019: 15 · 2012: 1
FWCI
47.59
Type
journal article
Language
en
Open access
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship@UMassChan (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion)
  • Apollo (University of Cambridge) (submittedVersion)
  • Apollo
Funders
  • Wellcome Trust (108139, 108139/B/15/Z, 108139/Z/15/Z)
  • Multiple Sclerosis Society
  • Rosetrees Trust (M525-CD2)
  • Cambridge University Hospitals (146281)
  • Medical Research Council (MC_PC_12009, MR/K008803/1, MR/M010503/1)
  • Biotechnology and Biological Sciences Research Council (1517905, BB/I013210/1)
  • National Human Genome Research Institute (U41HG002371)
  • National Institute of Neurological Disorders and Stroke (F32NS103266, R35NS097305, R01NS040511)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
Keywords
multiple sclerosis, neuronal vulnerability, meningeal inflammation, reactive astrocytes, microglial activation, macrophages, MS plaques, long non-coding RNA, glial activation, single-nucleus RNA sequencing
MeSH terms
RNA-Seq, Adult, Animals, Astrocytes, Autopsy, Female, Humans, Macrophages, Male, Middle Aged, Multiple Sclerosis, Myelin Sheath, Neurons, Oligodendroglia, Phagocytosis, RNA, Small Nuclear, Cryopreservation, Microglia, Homeodomain Proteins, Cell Lineage, Mice, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review